Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines
- PMID: 10473114
Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines
Abstract
Because regional spread to lymph nodes without systemic spread is a relatively common event in squamous cell cancer of the head and neck (SCCHN), it is possible that lymphoid-related receptors or cytokines might directly impact the growth of these tumors. In the present study, we have shown by flow cytometry and Western blotting that the central lymphoid regulatory molecule, CD40, is expressed on the surface of all seven SCCHN tumor cell lines studied. Tumor cell lines also expressed epidermal growth factor (EGF) receptor, MHC class I, and CD95 (Fas) but did not uniformly express other important lymphoid regulatory molecules such as CD80, CD86, or interleukin (IL) 2 receptor components. CD40 ligation by trimeric CD40 ligand (CD40L) resulted in a 20-45% inhibition of tumor cell growth in three of seven cell lines tested. The cytokines IL-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-10, IL-11, and IL-15 neither inhibited nor stimulated growth in any of the cell lines tested. EGF had pleiotropic effects on cell growth; it inhibited growth in two cell lines, stimulated growth in one cell line, and had no effect in four cell lines. When coligation by EGF and CD40L was studied, additive or supra-additive growth inhibition was seen in four cell lines. Three cell lines were unaffected by EGF, CD40, or coligation with both reagents. Examination of tumor tissues from 12 previously untreated patients representing a broad spectrum of patients presenting with SCCHN demonstrated CD40 expression in all 12 tumor specimens. This study supports the notion that CD40 is a regulatory molecule for the growth of SCCHN. The important role of CD40-CD40L interactions in the regulation of immune cells in the lymph node and the unique high-level expression of CD40L by these immune cells lend support to the hypothesis that this ligand/receptor pair is an important mediator of cell growth in SCCHN.
Similar articles
-
CD40 function in squamous cell cancer of the head and neck.Oral Oncol. 2005 May;41(5):462-9. doi: 10.1016/j.oraloncology.2004.11.005. Oral Oncol. 2005. PMID: 15878750
-
Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4.Clin Cancer Res. 1996 Jan;2(1):127-35. Clin Cancer Res. 1996. PMID: 9816099
-
Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.Clin Cancer Res. 2001 Mar;7(3):691-703. Clin Cancer Res. 2001. PMID: 11297266
-
The role of peptide growth factors in head and neck carcinoma.Otolaryngol Clin North Am. 1992 Oct;25(5):1105-15. Otolaryngol Clin North Am. 1992. PMID: 1408194 Review.
-
[Transforming growth factor alpha and head and neck neoplasms].Zhonghua Er Bi Yan Hou Ke Za Zhi. 1992;27(6):363-5. Zhonghua Er Bi Yan Hou Ke Za Zhi. 1992. PMID: 1303671 Review. Chinese. No abstract available.
Cited by
-
Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.Oncotarget. 2016 Sep 6;7(36):58684-58695. doi: 10.18632/oncotarget.11017. Oncotarget. 2016. PMID: 27494901 Free PMC article. Review.
-
Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.Oncologist. 2017 Jun;22(6):680-693. doi: 10.1634/theoncologist.2016-0318. Epub 2017 May 15. Oncologist. 2017. PMID: 28507203 Free PMC article. Review.
-
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Eur J Cancer. 2017 May;76:152-166. doi: 10.1016/j.ejca.2016.12.035. Epub 2017 Mar 18. Eur J Cancer. 2017. PMID: 28324750 Free PMC article. Review.
-
Spatial characterization and quantification of CD40 expression across cancer types.BMC Cancer. 2023 Mar 9;23(1):220. doi: 10.1186/s12885-023-10650-7. BMC Cancer. 2023. PMID: 36894898 Free PMC article.
-
The dark side of immunotherapy: pancreatic cancer.Cancer Drug Resist. 2020 May 11;3(3):491-520. doi: 10.20517/cdr.2020.13. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582441 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous